SAN DIEGO, March 17, 2015 /PRNewswire/ -- Sequenom, Inc.
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, today announced that its Board of Directors elected
Kenneth Buechler, Ph.D. as Chairman
of the Board, effective April 1,
2015. Dr. Buechler succeeds Harry
Hixson, Jr., Ph.D. who will retire from the position
effective March 31, 2015, after 11
years of service.
"We are extremely appreciative of Dr. Hixson's commitment and
service to the board of directors for the past 11 years," said
Bill Welch, President and Chief
Executive Officer of Sequenom. "His leadership and passion for
innovation have played a significant role in Sequenom's success in
the noninvasive prenatal testing market."
Incoming chairman, Dr. Buechler, has served on the board of
directors since December 2009. Prior
to joining Sequenom's board, he served as President and Chief
Scientific Officer of Biosite Incorporated, which he co-founded.
Prior to co-founding Biosite, Dr. Buechler was a senior research
scientist for the diagnostics research and development group at
Hybritech Incorporated. He also is a director of Quidel Corp.,
Sotera Wireless Inc., Edico Genome Inc., and Astute Medical
Inc.
"I am honored to begin my new role and look forward to working
closely with the board and Sequenom management team as the Company
continues to expand its portfolio of tests to provide additional
offerings to health care providers and their patients," said Dr.
Buechler.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier
lives through the development of innovative products and
services. The Company serves patients and physicians by
providing early patient management information.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding the development of
innovative products and services, the anticipation of Dr.
Buechler assuming the position of Chairman of the Board of
Directors on April 1, 2015 and the
continued expansion of its portfolio of tests to provide additional
offerings to health care providers and their patients. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Risks are described more
fully in the Company's filings with the Securities
and Exchange Commission, including without limitation the Company's
most recent Annual Report on Form 10-K and other documents
subsequently filed with or furnished to the Securities and
Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. The Company undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kenneth-buechler-elected-chairman-of-sequenom-board-of-directors-300051256.html
SOURCE Sequenom, Inc.